Featured Attorney
Rolando R. Sanchez
Associate
Mr. Sanchez defends complex lawsuits, including mass tort claims and claims involving international plaintiffs. He is experienced in dealing with high-level foreign diplomats and foreign enforcement entities, as well as U.S. federal and military agencies. Read more >
Verdicts & Opinions
-
Irby v. Novartis Pharm. Corp., No. MID-l-1815-08 MT (N.J. Super. Ct. May 11, 2012)
New Jersey court denies plaintiff’s motion to reconsider order granting summary judgment to Novartis Pharmaceuticals Corporation.
-
Brodie v. Novartis Pharmaceuticals Corporation, No. 4:10-CV-138-HEA (E.D. Mo. April 11, 2012)
In yet another victory for Novartis, the United States Court of Appeals for the Eighth Circuit dismisses plaintiff’s appeal.
-
Lemons v. Novartis Pharm. Corp., No. 3:08-cv-00361 (W.D.N.C. Order March 21, 2012)
Federal court in Zometa® litigation excludes most of plaintiff's FDA expert's proffered testimony.
-
In re: Pamidronate Products Liab. Litig., No.1:09-MD-2120 (KAM) (E.D.N.Y. Jan. 30, 2012)
Firm client Sandoz Inc. exits MDL after federal district court finds product liability claims preempted.
-
Harvey v. Novartis Pharm. Corp., No. 2:06-CV-1140-VEH (N.D. Ala. Jan. 12, 2012)
Plaintiff's untimely effort to designate retained expert witness on specific causation rejected by the Northern District of Alabama in Aredia®/Zometa® case.
Upcoming Events
-
On Friday, May 4th, Firm Partner Rebecca Womeldorf parrticipated in a panel for the Attorneys General Education Program Public Policy Conference, The Pharmaceutical Industry: Economics, Regulation, and Legal Issues.
-
-
Firm hosts Women's Bar Association of D.C. April event, How to Become an Administrative Law Judge.
-
-
News & Publications
-
Hollingsworth LLP named again to the National Law Journal's Midsize Firm Hot List.
-
Lawyers Have Heart, Washington DC -- June 9, 2012
For more than fifteen years, Hollingsworth LLP has been a major sponsor of the annual Lawyers Have Heart 10K Run, which, since its creation, has raised more than $7.5 million to benefit the American Heart Association. The Firm typically sends more than fifty of its employees on this 6.2 mile run though the streets of Georgetown and along Rock Creek in the Washington area's largest 10K event. The race is one of several charitable activities Hollingsworth LLP participates in as a firm. Click here for more information on this year's run.
-
Manning the Daubert Gate: A Defense Primer in Response to Milward v. Acuity Specialty Products
Eric G. Lasker, Hollingsworth LLP Partner, and Chair of the Toxics & Haardous Substances Committee of the International Association of Defense Counsel, authors article for the April 2012 Defense Counsel Journal.
-
Addressing an audience of in-house counsel and corporate leaders, the Firm presented on topics trending in the defense of complex litigation.
-
Hollingsworth LLP sponsors the prestigious Sedona ConferenceŽ Working Group Series
-
Partner Michael L. Junk and Associate John McNulty co-author article for LJN's Product Liaiblity Law & Strategy newsletter.
-
"Novartis has been on a roll recently in the Zometa litigation, winning a summary judgment ruling in October in Atlanta federal district court and securing a dismissal in Fort Smith, Ark. federal district court in January, as its trial teams from Hollingsworth LLP, Fagre Baker Daniels, Foley & Mansfield, and Stites & Harbison won back-to-back jury verdicts in Kentucky and St. Louis in cases involving the company's cancer drug, Zometa."
-
Daubert Alert: The First Circuit Takes a Step Back in Milward v. Acuity Specialty Products
Hollingsworth LLP partner, Eric G. Lasker, authors article forThe Metropolitan Corporate Counsel. Mr. Lasker was amicus counsel for a coalition of industry associations in support of the Milward petition for writ of certiorari.
-
St. Louis Federal Jury Returns Verdict for Novartis in Second ZometaŽ Defense Verdict this Week
On two consecutive days this week, two different federal juries returned defense verdicts in favor of Firm client Novartis Pharmaceuticals Corporation, marking the second and third federal defense verdicts in a row for Novartis in litigation arising out of the federal MDL, In re Aredia® and Zometa® Prods. Liab. Litig.
-
Partner Eric G. Lasker and Associate Lori M. Farrelly co-author article for International Association of Defense Counsel Toxics & Hazardous Substances Litigation Committee Newsletter.
-
Parties await date for oral argument after conclusion of appellate briefing in Bessemer v. Novartis Pharms. Corp., No. A-002069-10T1 (N.J. Super. Ct. App. Div.)
-
Final Philadelphia Gadolinium-Based Contrast Agent personal injury case dismissed.
